Protagonist Therapeutics (PTGX) FY2024 results: revenue $434 million, up 624.1% on the year
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $434 million for fiscal 2024, the year ended 31 December 2024, up 624.1% on the year before. Net income was $275 million, and diluted earnings per share $4.23. The figures are the company's own, from the 10-K it filed with the SEC on 21 February 2025.
Revenue
$434 million
+624.1% on the year
FY2017FY2024
Operating margin
58.2%
-156.1% a year earlier
FY2017FY2024
Net income
$275 million
FY2017FY2024
Diluted EPS
$4.23
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
184
-70.2
-108
Capital expenditure
1.4
0.6
0.8
+122.5%
Free cash flow
183
-70.8
-109
Free cash flow margin
42.1%
-118.1%
-409.8%
Cash from investing
-299
-39.3
91.5
Cash from financing
25.9
170
18.8
-84.8%
Depreciation and amortisation
0.8
1.0
1.0
-15.5%
Share-based compensation
37.6
29.3
24.2
+28.2%
Diluted shares, weighted
65m
57m
49m
+14.6%
Shares outstanding at period end
61m
58m
49m
+5.8%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
675
337
216
+100.6%
Debt
0.0
n/a
0.0
Operating lease liabilities
10.4
n/a
1.1
Other liabilities
59.1
21.3
31.2
+177.7%
Total liabilities and equity
745
358
248
+108.1%
Fixed assets
3.2
1.2
1.6
+166.9%
Investments
462
155
112
+198.2%
Cash and equivalents
97.2
187
126
-47.9%
Other assets
182
15.1
9.0
+1,104.6%
Total assets
745
358
248
+108.1%
10-K for the year ended 31 December 2024, filed 21 February 2025: the filing.